Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study. // Endocrine Practice. – URL: https://www.sciencedirect.com/science/article/pii/S1530891X26010426?dgcid=rss_sd_all
Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study. Endocrine Practice. https://www.sciencedirect.com/science/article/pii/S1530891X26010426?dgcid=rss_sd_all
“Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.” Endocrine Practice.
@article{article44454,
title = {Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study},
journal = {Endocrine Practice},
url = {https://www.sciencedirect.com/science/article/pii/S1530891X26010426?dgcid=rss_sd_all}
}